Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study
| Autor: | Wolfgang E. Schmidt, John B. Buse, Marcin Zychma, Jørgen S. Christiansen, M. Hammer |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Randomization Liraglutide business.industry Endocrinology Diabetes and Metabolism Type 2 diabetes Hypoglycemia medicine.disease Surgery Metformin Endocrinology Patient satisfaction Internal medicine Diabetes mellitus Internal Medicine medicine business Exenatide medicine.drug |
| Zdroj: | Diabetic Medicine. 28:715-723 |
| ISSN: | 0742-3071 |
| DOI: | 10.1111/j.1464-5491.2011.03276.x |
| Popis: | Diabet. Med. 28, 715–723 (2011) Abstract Aims The Liraglutide Effect and Action in Diabetes 6 trial was an open-label trial comparing liraglutide with exenatide as an ‘add-on’ to metformin and/or sulphonylurea. Methods Patients with Type 2 diabetes were randomized to liraglutide 1.8 mg once daily or exenatide 10 μg twice daily for 26 weeks. This was followed by a 14-week extension phase, in which all patients received liraglutide 1.8 mg once daily. Results Patient-reported outcomes were measured in 379 patients using Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and DTSQ change (DTSQc). The change in overall treatment satisfaction (DTSQs score) from baseline at week 26 with liraglutide was 4.71 and with exentaide was 1.66 [difference between groups 3.04 (95% CI 1.73–4.35), P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text